OR5J2 inhibitors refer to a specific class of chemical compounds that target and inhibit the function of the olfactory receptor OR5J2, a member of the G protein-coupled receptor (GPCR) superfamily. OR5J2 is predominantly found in the olfactory epithelium, where it plays a role in odor recognition by binding specific volatile compounds and triggering signal transduction pathways that lead to the perception of smell. These inhibitors are designed to interfere with the receptor's ability to bind its natural ligands, thereby modulating the olfactory signal transduction. The mechanism of inhibition may involve competitive binding at the active site, allosteric modulation, or structural changes to the receptor that prevent proper signal transmission through the associated G proteins. The development of OR5J2 inhibitors often involves detailed molecular studies to understand the binding dynamics of the receptor and identify key residues responsible for ligand interaction.
Inhibitors of GPCRs, like OR5J2, can vary widely in their chemical structure, depending on the nature of the interaction with the receptor. These compounds may be small organic molecules or larger, more complex macromolecules, each designed to exploit specific features of the OR5J2 receptor's conformation and binding pockets. Chemical design strategies often incorporate techniques such as computational modeling, structure-activity relationship (SAR) studies, and high-throughput screening to optimize the inhibitory potency and selectivity. Understanding the structural basis for ligand recognition by OR5J2 has led to the design of compounds that exhibit high specificity, minimizing off-target effects on other olfactory receptors. The synthesis of these inhibitors involves a range of chemical reactions tailored to enhance their binding affinity, stability, and molecular interactions with the receptor. Furthermore, the study of OR5J2 inhibitors can contribute to a broader understanding of GPCR signaling and receptor-ligand interactions at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin could directly inhibit the transcription of OR5J2 by obstructing RNA polymerase II, leading to a decrease in the OR5J2 mRNA and protein levels. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine might induce hypomethylation of the OR5J2 gene promoter, thereby aberrantly activating repressor proteins that could downregulate OR5J2 expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
TSA could lead to hyperacetylation of histones associated with the OR5J2 gene, causing chromatin remodeling that results in reduced transcriptional activity of the OR5J2 gene. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine may disrupt endosomal acidification and lysosomal enzymes, potentially causing accumulation of misfolded OR5J2 proteins and thus reducing their expression on the cell surface. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin might downregulate OR5J2 expression by inhibiting the mTOR pathway, which is crucial for cap-dependent mRNA translation, including that of the OR5J2 mRNA. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D could bind to DNA sequences at the OR5J2 locus, preventing the advancement of RNA polymerase and leading to a sharp decrease in OR5J2 transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine may decrease DNA methylation on the OR5J2 gene, potentially leading to the recruitment of methyl-CpG-binding domain proteins that repress OR5J2 transcription. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A can bind to G-C rich DNA sequences in the OR5J2 promoter region, potentially obstructing the binding of essential transcription factors and thus decreasing OR5J2 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 could inhibit the MEK1/2 proteins, leading to a decrease in ERK1/2 phosphorylation and the downstream transcriptional activity necessary for OR5J2 gene expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 might inhibit PI3K, leading to a decrease in AKT phosphorylation and subsequent downregulation of transcription factors necessary for OR5J2 expression. | ||||||